Forde PM et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 2018;378)21):1976-86. Abstract

Forde PM et al.Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial. AACR 2021;Abstract CT003.

Herbst R et al. Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. ASCO 2020;Abstract LBA5.

Love N et al. Evaluating the potential utility of presenting breast cancer clinical investigator estimates for numeric treatment benefit and recommendations for the use of two anti-HER2 adjuvant therapies: HER RISK. SABCS 2019;Abstract P1-18-23.

Spicer J et al. Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). ASCO 2021;Abstract 8503.

Wakelee HA et al. IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). ASCO 2021;Abstract 8500.

Wu YL et al. Osimertinib in resected EGFR-mutated non–small-cell lung cancer. N Engl J Med 2020;383(18):835-35. Abstract